METHODS: We retrospectively reviewed the PLUS database to identify patients who had IVADAs and were treated with PEDs from 2014 to 2019 at 14 centers across China. Data including patient and aneurysm characteristics, procedure details, angiographic and clinical results, relationship with the ipsilateral posterior inferior cerebellar artery (PICA), and patency of the PICA following PED coverage were analyzed.
RESULTS: In this study 52 consecutive patients with 52 IVADAs were included. The mean age was 52.33 years and 82.7% were male. With a median follow-up of 10.5 months, the complete occlusion rate was 93.8% (45/48) and no recurrence or in-stent stenosis was detected. The total postoperative complication rate and mortality were 11.5% and 1.9%, respectively. Complications occurred in 9.6% (5/52) of patients within 30 days after the operation, including ischemic stroke in 3 and hemorrhagic stroke in 2. Another patient suffered an ischemic stroke at follow-up, 78.8% (41/52) PICAs were covered by PEDs, 1 case (2.4%) had a functional disability due to PICA occlusion, while 39.0% (16/41) had reduced flow during follow-up but hardly caused any obvious neurological deficits. Patients with IVADA involving PICA had a trend towards more complications (66.7% vs. 51.1%; P = 1).
CONCLUSIONS: Treating IVADAs with PEDs may be a safe and effective option, with favorable clinical and angiographic outcomes; however, complications associated with this treatment should not be ignored.
BACKGROUND: http://www.
RESULTS: gov . Unique identifier: NCT03831672.
方法:我们回顾性回顾了PLUS数据库,以确定2014年至2019年在中国14个中心接受IVADAs治疗并接受PEDs治疗的患者。数据包括患者和动脉瘤特征,程序详细信息,血管造影和临床结果,与同侧小脑后下动脉(PICA)的关系,并分析了PED覆盖后PICA的通畅性。
结果:在这项研究中,纳入了52例IVADAs的连续患者。平均年龄为52.33岁,男性占82.7%。中位随访时间为10.5个月,完全闭塞率为93.8%(45/48),未发现复发或支架内狭窄.术后总并发症发生率和死亡率分别为11.5%和1.9%,分别。9.6%(5/52)的患者在术后30天内出现并发症,包括3例缺血性卒中和2例出血性卒中。另一名患者在随访中出现缺血性中风,78.8%(41/52)的PICA被PED覆盖,1例(2.4%)因PICA闭塞导致功能障碍,而39.0%(16/41)的患者在随访期间流量减少,但几乎没有引起任何明显的神经功能缺损。涉及PICA的IVADA患者有更多并发症的趋势(66.7%与51.1%;P=1)。
结论:用PEDs治疗IVADAs可能是一种安全有效的选择,具有良好的临床和血管造影结果;然而,与这种治疗相关的并发症不容忽视.
背景:http://www.
结果:政府。唯一标识符:NCT03831672。